assistance reporting documents, and the second through a voluntary best practices reporting form.

Respondents: States, District of Columbia, Guam, Puerto Rico and Virgin Islands.

Annual Burden Estimates:

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Needs Assessment	54	1	16	864
Technical Assistance Request/Report	54	1	3	162
Best Practices Report	54	1	3	162

Estimated Total Annual Burden Hours: 1,188.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: December 5, 1996.

Douglas J. Godesky,

Reports Clearance Officer.

[FR Doc. 96–31377 Filed 12–10–96; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 96M–0472]

Neuromedical Systems, Inc.; Premarket Approval of the PAPNET® Testing System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Neuromedical Systems, Inc., Suffern, NY, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the PAPNET® Testing System. After reviewing the recommendation of the Hematology and Pathology Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of November 8, 1995, of the approval of the application.

DATES: Petitions for administrative review by January 10, 1997.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Peter E. Maxim, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1293.

SUPPLEMENTARY INFORMATION: On September 21, 1994, Neuromedical Systems, Inc., Suffern, NY 10901–4164, submitted to CDRH an application for premarket approval of the PAPNET® Testing System. The device is a semi-automated test indicated to aid in the rescreening of cervical Papanicolaou (Pap) smears previously reported as negative. The PAPNET® Testing System is intended to detect evidence of cervical epithelial abnormalities including the following categories of the Bethesda System for classification of cervical cytology results: (1) Primary squamous cell carcinoma of the cervix and its possible precursor lesions, i.e., low grade squamous intra epithelial lesions (LGSIL), high grade intra epithelial (HGSIL), and atypical squamous cells of undetermined significance (ASCUS); and (2) primary endocervical adenocarcinoma and its possible precursor lesion, atypical glandular cells of undetermined significance (AGUS). The PAPNET® testing is intended as an adjunct to all standard laboratory quality control and mandated re-screening procedures.

On August 7, 1995, the Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On November 8, 1995, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under 21 CFR part 12 of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under 21 CFR 10.33(b). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a

notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before January 10, 1997, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: October 24, 1996.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 96–31422 Filed 12–10–96; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Advisory Council, Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of January 1997:

Name: Advisory Committee on Infant Mortality.

Date and Time: January 9, 1997, 9:00 a.m.; January 10, 1997, 8:30 a.m.

Place: Radisson Barcelo Hotel, 2121 P Street, N.W., Washington, DC 20037. The meeting is open to the public.

Agenda: Topics that will be discussed include: Updates on the Healthy Start Program, Evaluation, and Media Campaign; the Southern Governor's infant mortality initiatives; and Teenage Pregnancy Prevention Programs.

Anyone requiring information regarding the Committee should contact Dr. Peter van Dyck, Executive Secretary, Advisory Committee on Infant Mortality, Health Resources and Services Administration, Room 18–31, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–2204.

Persons interested in attending any portion of the meeting or having questions regarding the meeting should contact Ms. Kerry P. Nesseler, Maternal and Child Health Bureau, Health Resources and Services Administration, Telephone (301) 443–2204.

Agenda Items are subject to change as priorities dictate.

Dated: December 5, 1996.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 96–31421 Filed 12–10–96; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Receipt of Applications for Permit

The following applicants have applied for a permit to conduct certain activities with endangered species. This notice is provided pursuant to Section 10(c) of the Endangered Species Act of 1973, *as amended* (16 U.S.C. 1531, *et seq.*):

Applicant: Jeffry Eberhart, Dallas, GA, PRT–822430.

The applicant requests a permit to import the sport-hunted trophy of one male bontebok (*Damaliscus pygargus dorcas*) culled from a captive herd maintained under the management program of the Republic of South Africa, for the purpose of enhancement of the survival of the species.

Applicant: Dewey Morrison Dalton, Dallas, TX, PRT–822764.

The applicant requests a permit to import the sport-hunted trophy of one male bontebok (*Damaliscus pygargus dorcas*) culled from a captive herd maintained under the management program of the Republic of South Africa, for the purpose of enhancement of the survival of the species.

Applicant: Derek Baker, San Jose, CA, PRT–821239.

The applicant amends a request for a permit to import 25 Asian bonytongue (*Scleropages formosus*) from P.S. Bintang Kalbor, Lakimantan, Indonesia for the purpose of survival of the species through propagation. The original request was to import three Asian bonytonque and the notification appeared in the Federal Register Vol. 61. No. 26, page 55013, published October 23, 1996, pursuant to Section 10(c) of the Endangered Species Act of 1973, as amended (16 U.S.C. 1531, *et seq.*)

Applicant: Teri Embery, Bartlesvillew, OK, PRT–822244.

On November 20, 1996, Federal Register/Vol. 61, No. 225, page 59106, column 3, the following notice was published:

The applicant requests a permit for the import of one captive-born female leopard cat (*Prionailurus b. bengalensis*) from Jungle Cat World, Ontario, Canada for the purpose of enhancement of the survival of the species through propagation.

The animal requested in this application should have been listed as a male.

Written data or comments should be submitted to the Director, U.S. Fish and Wildlife Service, Office of Management Authority, 4401 North Fairfax Drive, Room 430, Arlington, Virginia 22203, and must be received by the Director within 30 days of the date of this publication.

The public is invited to comment on the following application(s) for permits to conduct certain activities with marine mammals. The application(s) was/were submitted to satisfy requirements of the Marine Mammal Protection Act of 1972, *as amended* (16 U.S.C. 1361 *et seq.*) and the regulations governing marine mammals (50 CFR 18).

Applicant: Point Defiance Zoo and Aquarium, Tacoma, WA, PRT–822531.

Type of Permit: Import for public display.

Name and Number of Animals: Polar Bear (*Ursus maritimus*), 2.

Summary of Activity to be Authorized: The applicant has requested a permit to import two polar bears presently held at the Calgary Zoo, Canada, which were legally removed from the wild at Churchill, Manitoba.

Source of Marine Mammals for Research/Public Display: Canada.

Period of Activity: Up to five years from issuance of a permit, if issued.

Concurrent with the publication of this notice in the Federal Register, the Office of Management Authority is forwarding copies of this application to the Marine Mammal Commission and the Committee of Scientific Advisors for their review.

Written data or comments, requests for copies of the complete application, or requests for a public hearing on this application should be sent to the U.S. Fish and Wildlife Service, Office of Management Authority, 4401 N. Fairfax Drive, Room 430, Arlington, Virginia 22203, telephone 703/358–2104 or fax 703/358–2281 and must be received within 30 days of the date of publication of this notice. Anyone requesting a hearing should give specific reasons why a hearing would be appropriate. The holding of such hearing is at the discretion of the Director.

Documents and other information submitted with these applications are available for review, *subject to the requirements of the Privacy Act and Freedom of Information Act*, by any party who submits a written request for